Hironari Hanaoka1, Harunobu Iida2, Tomofumi Kiyokawa2, Yukiko Takakuwa2, Kimito Kawahata2. 1. Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan. hhanaoka1208@yahoo.co.jp. 2. Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, 216-8511, Japan.
Abstract
OBJECTIVE: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. METHODS: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). RESULTS: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. CONCLUSIONS: Our results suggest that the cessation of all drugs is associated with disease flare for SLE patients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy. Key Point • Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.
OBJECTIVE: To study maintenance therapy after achievement of the lowest possible disease activity in systemic lupus erythematosus (SLE) without major organ manifestations. METHODS: We retrospectively evaluated patients with SLE who visited our hospital from Jan 2015 to Feb 2018 and were taking prednisolone (PSL) < 10 mg/day. After excluding those with neuropsychiatric SLE or severe lupus nephritis, patients were divided into four groups according to their maintenance monotherapy treatment, namely, prednisolone (PSL), immunosuppressant (IS), hydroxychloroquine (HCQ), and no drugs. The groups were then compared with regard to cumulative flare rate and changes in SLE Disease Activity Index (SLEDAI). RESULTS: There were 47 patients on PSL, 10 on IS, 5 on HCQ, and 11 on no drugs. Flare rate was higher in the no drug group, and no patients with the IS or HCQ group experienced a flare (p = 0.003). A reduction in SLEDAI was only seen in the IS and HCQ groups (p = 0.05 and p = 0.03, respectively). There were no differences in adverse events among groups during the study period. CONCLUSIONS: Our results suggest that the cessation of all drugs is associated with disease flare for SLEpatients without major organ manifestations. IS or HCQ monotherapy might be a reasonable maintenance strategy comparing with steroid monotherapy. Key Point • Immunosuppressant or hydroxychloroquine monotherapy appears to be a reasonable maintenance strategy.
Authors: Caroline Gordon; Maame-Boatemaa Amissah-Arthur; Mary Gayed; Sue Brown; Ian N Bruce; David D'Cruz; Benjamin Empson; Bridget Griffiths; David Jayne; Munther Khamashta; Liz Lightstone; Peter Norton; Yvonne Norton; Karen Schreiber; David Isenberg Journal: Rheumatology (Oxford) Date: 2018-01-01 Impact factor: 7.580
Authors: Jan J Weening; Vivette D D'Agati; Melvin M Schwartz; Surya V Seshan; Charles E Alpers; Gerald B Appel; James E Balow; Jan A Bruijn; Terence Cook; Franco Ferrario; Agnes B Fogo; Ellen M Ginzler; Lee Hebert; Gary Hill; Prue Hill; J Charles Jennette; Norella C Kong; Philippe Lesavre; Michael Lockshin; Lai-Meng Looi; Hirofumi Makino; Luiz A Moura; Michio Nagata Journal: J Am Soc Nephrol Date: 2004-02 Impact factor: 10.121
Authors: Bernardo A Pons-Estel; Luis J Catoggio; Mario H Cardiel; Enrique R Soriano; Silvana Gentiletti; Antonio R Villa; Isaac Abadi; Francisco Caeiro; Alejandro Alvarellos; Donato Alarcón-Segovia Journal: Medicine (Baltimore) Date: 2004-01 Impact factor: 1.889
Authors: Ronald F van Vollenhoven; Marta Mosca; George Bertsias; David Isenberg; Annegret Kuhn; Kirsten Lerstrøm; Martin Aringer; Hendrika Bootsma; Dimitrios Boumpas; Ian N Bruce; Ricard Cervera; Ann Clarke; Nathalie Costedoat-Chalumeau; László Czirják; Ronald Derksen; Thomas Dörner; Caroline Gordon; Winfried Graninger; Frédéric Houssiau; Murat Inanc; Søren Jacobsen; David Jayne; Anna Jedryka-Goral; Adrian Levitsky; Roger Levy; Xavier Mariette; Eric Morand; Sandra Navarra; Irmgard Neumann; Anisur Rahman; Jozef Rovensky; Josef Smolen; Carlos Vasconcelos; Alexandre Voskuyl; Anne Voss; Helena Zakharova; Asad Zoma; Matthias Schneider Journal: Ann Rheum Dis Date: 2014-04-16 Impact factor: 19.103